

## EZH2 Contributes to 5-FU Resistance in Gastric Cancer by Epigenetically Suppressing FBXO32 Expression [Retraction]

Wang C, Li X, Zhang J, Ge Z, Chen H, Hu J. *Onco Targets Ther.* 2018;11:7853–7864.

We, the Editors and Publisher of *OncoTargets and Therapy*, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images in Figures 2, 3, 4 and 5. Specifically,

- The western blot images for Figure 2C, AGS/5-FU and Figure 2D, SGC-7901/5-FU, have been duplicated.
- The flow cytometry images for Figure 2H, SGC-7901/5-FU and Figure 4H, SGC-7901/5-FU, have been duplicated.
- The western blot bands for Figure 3B, AGS/5-FU and SGC-7901/5-FU, have been duplicated.
- The western blot bands for Figure 5A, AGS/5-FU and Figure 5B, SGC-7901/5-FU, have been duplicated.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.